Search Results 221-230 of 17535 for Assay
Natera has developed an assay called Prospera™ to detect the amount of donor-derived cell-free DNA (dd-cfDNA), which is a marker of kidney rejection.
... assay, our lab can measure the inherent seeding ability of abnormal tau species in patient samples. We hope that the use of this assay will allow us to gain ...
The study also aims to develop a biomarker assay to detect circulating antigen in patients infected with Coccidioides. Participation eligibility. Participant ...
... assays or sectioned to identify the specific cell types that were transduced. These assays are quite laborious requiring that one actually sections the ...
Rochester, Minn. The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, ...
... assay for predicting response to treatment on an individualized basis for Mayo Clinic cancer patients. Participation eligibility. Participant eligibility ...
... assay. Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation Rochester, MN. The purpose of this study is to compare edoxaban ...
Experts at Mayo Clinic, however, have noted a need to develop an in vivo assay to measure quality and quantity of regenerative outcomes in transplant ...
... assay for the detection of mutations associated with uveal melanoma. The performance characteristics of the ddPCR assay for the detection of ctDNA mutation ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.